Adjuvants: Friends in Vaccine Formulations Against Infectious Diseases

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 Jul 21

PMID 34288795

Citations 8

Authors

G G Guerrero Manriquez

I Tuero

Affiliations

Soon will be listed here.

Abstract

Infectious diseases represent a major cause of deaths worldwide. No vaccine or effective treatment exists nowadays, especially against intracellular pathogens. The increase in multiple drug and superbug antibiotic resistance strains, excessive medication, or misuse of drugs has prompted the search for other safe and effective alternatives. Consistent with this, adjuvants (Latin word "adjuvare": "help or aid") co-administered (Exo) in vaccines have emerged as a promising alternative to initiate and boost an innate, downstream signal that led to adaptative immune response. Nowadays, a promising model of strong immunogens and adjuvants at mucosal sites are the microbial bacterial toxins. Other adjuvants that are also used and might successfully replace aluminum salts in combination with nanotechnology are CpG-ODN, poly IC, type I IFNs, mRNA platforms. Therefore, in the present review, we focused to revisit the old to the new adjuvants compounds, the properties that make them friends in vaccine formulations against infectious diseases.

Citing Articles

Oral Live-Carrier Vaccine of Recombinant Lactococcus lactis Inducing Prophylactic Protective Immunity Against Helicobacter pylori Infection.

Ni X, Liu Y, Sun M, Jiang Y, Wang Y, Ke D Probiotics Antimicrob Proteins. 2024; .

PMID: 39251521 DOI: 10.1007/s12602-024-10360-x.

Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.

Wang G, Verma A, Guan X, Bu F, Odle A, Li F J Virol. 2024; 98(9):e0037624.

PMID: 39189731 PMC: 11449030. DOI: 10.1128/jvi.00376-24.

New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.

Demoulins T, Techakriengkrai N, Ebensen T, Schulze K, Liniger M, Gerber M Methods Mol Biol. 2024; 2786:89-133.

PMID: 38814391 DOI: 10.1007/978-1-0716-3770-8_4.

Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies.

Wang H, Wang S, Fang R, Li X, Xing J, Li Z Vaccines (Basel). 2024; 12(1).

PMID: 38250851 PMC: 10820143. DOI: 10.3390/vaccines12010038.

Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens.

Tognetti F, Biagini M, Denis M, Berti F, Maione D, Stranges D Int J Mol Sci. 2023; 24(15).

PMID: 37569427 PMC: 10418901. DOI: 10.3390/ijms241512054.

References

Gonzalez-Navajas J, Lee J, David M, Raz E . Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012; 12(2):125-35. PMC: 3727154. DOI: 10.1038/nri3133. View

Walker L . EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis. Immunol Lett. 2017; 184:43-50. DOI: 10.1016/j.imlet.2017.02.007. View

Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert R, McGhee J, Yuki Y . Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012; 11(3):367-79. PMC: 3315788. DOI: 10.1586/erv.11.196. View

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao G . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020; 21(1):39-51. PMC: 7561304. DOI: 10.1016/S1473-3099(20)30831-8. View

Da Hora V, Conceicao F, Dellagostin O, Doolan D . Non-toxic derivatives of LT as potent adjuvants. Vaccine. 2010; 29(8):1538-44. DOI: 10.1016/j.vaccine.2010.11.091. View

Fritz J, Ferrero R, Philpott D, Girardin S . Nod-like proteins in immunity, inflammation and disease. Nat Immunol. 2006; 7(12):1250-7. DOI: 10.1038/ni1412. View

Legorreta-Herrera M, Meza R, Moreno-Fierros L . Pretreatment with Cry1Ac protoxin modulates the immune response, and increases the survival of Plasmodium-infected CBA/Ca mice. J Biomed Biotechnol. 2010; 2010:198921. PMC: 2837902. DOI: 10.1155/2010/198921. View

Di Pasquale A, Preiss S, Da Silva F, Garcon N . Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2):320-43. PMC: 4494348. DOI: 10.3390/vaccines3020320. View

Lin Y, Wang X, Huang X, Zhang J, Xia N, Zhao Q . Calcium phosphate nanoparticles as a new generation vaccine adjuvant. Expert Rev Vaccines. 2017; 16(9):895-906. DOI: 10.1080/14760584.2017.1355733. View

10.

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10):951-960. PMC: 7426884. DOI: 10.1001/jama.2020.15543. View

11.

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

12.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

13.

Thompson B, Chilton P, Ward J, Evans J, Mitchell T . The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol. 2005; 78(6):1273-80. DOI: 10.1189/jlb.0305172. View

14.

Schijns V . Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 2000; 12(4):456-63. DOI: 10.1016/s0952-7915(00)00120-5. View

15.

Rojas-Hernandez S, Rodriguez-Monroy M, Lopez-Revilla R, Resendiz-Albor A, Moreno-Fierros L . Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect Immun. 2004; 72(8):4368-75. PMC: 470623. DOI: 10.1128/IAI.72.8.4368-4375.2004. View

16.

Thiam F, Charpilienne A, Poncet D, Kohli E, Basset C . B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP specific antibody responses and induce a Th17-like response after intrarectal immunization. Microb Pathog. 2015; 89:27-34. DOI: 10.1016/j.micpath.2015.08.013. View

17.

Lycke N, Lebrero-Fernandez C . ADP-ribosylating enterotoxins as vaccine adjuvants. Curr Opin Pharmacol. 2018; 41:42-51. DOI: 10.1016/j.coph.2018.03.015. View

18.

Cai Y, Kurita-Ochiai T, Kobayashi R, Hashizume T, Yamamoto M . Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice. J Oral Sci. 2013; 55(2):107-14. DOI: 10.2334/josnusd.55.107. View

19.

Sambhara S, McElhaney J . Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol. 2009; 333:413-29. PMC: 7121450. DOI: 10.1007/978-3-540-92165-3_20. View

20.

Gonzalez-Gonzalez E, Garcia-Hernandez A, Flores-Mejia R, Lopez-Santiago R, Moreno-Fierros L . The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model. Vet Microbiol. 2014; 175(2-4):382-8. DOI: 10.1016/j.vetmic.2014.11.021. View